Company profile
DEFINIUM THERAPEUTICS, INC.
NASDAQ:DFTXMedicinal Chemicals and Botanical Products
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LYSERGIDE D-TARTRATE | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05407064 | phase2 | completed | 2022-08-24 | 2023-10-06 | Definium Therapeutics US, Inc. | A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms |
| NCT07303907 | phase2 | recruiting | 2025-12-03 | 2027-08-01 | Definium Therapeutics US, Inc. | A Phase 2A Trial of DT402 for Autism Spectrum Disorder |
| NCT06741228 | phase3 | active_not_recruiting | 2024-12-11 | 2026-07-15 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) |
| NCT07592689 | phase3 | recruiting | 2026-05-10 | 2027-09-01 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
| NCT06941844 | phase3 | active_not_recruiting | 2025-04-14 | 2026-05-20 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) |
FDA applications (0)
No records yet.